ANI Pharmaceuticals’ (ANIP) Buy Rating Reaffirmed at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating restated by investment analysts at Guggenheim in a note issued to investors on Monday,Benzinga reports. They currently have a $86.00 price objective on the specialty pharmaceutical company’s stock. Guggenheim’s target price would indicate a potential upside of 34.34% from the stock’s previous close.

Several other research firms have also weighed in on ANIP. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 target price for the company. HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Finally, Truist Financial upped their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $80.13.

ANI Pharmaceuticals Stock Down 3.4%

NASDAQ ANIP traded down $2.28 on Monday, reaching $64.02. The company had a trading volume of 166,819 shares, compared to its average volume of 290,708. The company’s fifty day moving average is $66.86 and its 200-day moving average is $60.70. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $77.00. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -116.56 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals’s revenue for the quarter was up 43.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.82 EPS. On average, research analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This represents a 1.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the sale, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock worth $197,792 over the last 90 days. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ANIP. US Bancorp DE raised its position in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the last quarter. KBC Group NV grew its holdings in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the last quarter. National Bank of Canada FI bought a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $79,000. GAMMA Investing LLC raised its holdings in ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 881 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in ANI Pharmaceuticals in the 4th quarter valued at approximately $166,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.